NCT05912946 is a Phase 2, PHASE3 clinical trial of Interferon in Interstitial Cystitis, sponsored by West China Hospital.

Who is sponsoring NCT05912946?

NCT05912946 is sponsored by West China Hospital.

What drugs are being tested in NCT05912946?

Interventions in NCT05912946: Interferon, Sodium Hyaluronate, Sodium Chloride Injection.

What condition does NCT05912946 study?

NCT05912946 studies Interstitial Cystitis.

Is NCT05912946 still recruiting?

NCT05912946 is currently status unknown. Last updated 15 September 2023.

Last reviewed 2023-09-15 · How we verify

NCT05912946

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessing the Effectiveness and Safety of Interferon Bladder Infusion for the Treatment of Interstitial Cystitis

Status unknown Phase 2, PHASE3 Last updated 15 September 2023

What this trial tests

Phase 2, PHASE3 trial testing Interferon in Interstitial Cystitis in 129 participants. Status unknown.

Timeline

15 October 2023

Primary endpoint
15 October 2024

15 October 2024

Quick facts

Lead sponsor	West China Hospital
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	129
Start date	15 October 2023
Primary completion	15 October 2024
Estimated completion	15 October 2024

Drugs / interventions tested

Interferon (INTERFERON) — full drug profile →
Sodium Hyaluronate — full drug profile →
Sodium Chloride Injection

Conditions studied

Interstitial Cystitis — all drugs for Interstitial Cystitis →

Sponsor

West China Hospital

Who can join

Eligibility, female only, with Interstitial Cystitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Interstitial cystitis/bladder pain syndrome (IC/BPS) is one of the most intractable diseases of Urogynecology. The main clinical manifestations of interstitial cystitis/bladder pain are frequent urination and severe overflowing bladder pain. Due to the unclear pathological mechanism and the diversity of clinical manifestations and pathological features of the disease, the diagnosis is mainly to exclude suspicious diseases. At present, IC/BPS treatment mainly includes oral administration of mast cell stabilizing drugs such as sodium pentosan sulfate and anticholinergic drugs, or bladder instillation of dimethyl sulfone, hyaluronic acid and other drugs directly acting on the bladder mucosa, or surgical treatment such as sacrospinal radiculotomy and peripheral denervation of the bladder, but all can only relieve clinical symptoms and improve quality of life, and can not be targeted etiological treatment according to the pathological mechanism. Research showed JC polyomavirus (JCPyV) virus may be the original pathogen causing the development of IC/BPS. Interferon, as a broad-body antiviral agent, plays a critical role in triggering innate and adaptive immune responses against viral replication and infection. It can inhibit the replication and transcription of JCPyV through a variety of pathways. Interferon may be a potential specific drug for IC/BPS. Therefore, this study aims to evaluate the efficacy and safety of interferon bladder perfusion for IC/BPS.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Intravesical Interferon Therapy vs Hyaluronic Acid for Pain Among Female Individuals With Interstitial Cystitis: A Randomized Clinical Trial.
Shen SH, Peng L, Zeng X, Zhang J, et al · · 2024 · cited 11× · PMID 38587846 · DOI 10.1001/jamanetworkopen.2024.4880

Verify or expand the search:

Other trials of Interferon

Trials testing the same drug.

NCT07199413 — Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I · Phase 1 · not yet recruiting
NCT05792878 — Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy · unknown
NCT04071353 — Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis C · unknown
NCT04030039 — Cohort Study of Clinical Outcomes in Chronic HBV Infection Patients With Low HBsAg Under Unplanned Intervention · unknown
NCT00577993 — Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients · Phase 3 · completed

Other recruiting trials for Interstitial Cystitis

Currently open trials in the same condition.

NCT06299683 — Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment · NA · recruiting
NCT05696444 — Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO) · NA · active not recruiting
NCT05485207 — Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome · EARLY_PHASE1 · active not recruiting
NCT04734847 — Motor Cortical Neuromodulation in Women With Interstitial Cystitis/Bladder Pain Syndrome · NA · recruiting
NCT00499317 — Genetic Study of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) · recruiting

Other West China Hospital trials

Trials by the same sponsor.

NCT07583654 — Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT07583914 — Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT07492914 — Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma · Phase 2 · recruiting
NCT07507097 — Study on the Optimal Head Position for Patients With Severe Acute Ischemic Stroke · NA · not yet recruiting
NCT07472933 — Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05912946 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by West China Hospital
Last refreshed: 15 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05912946.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing